Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Copenhagen, Denmark, April 23rd, 2025 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first and best-in-class ADCs for the treatment of cancers with high unmet medical need, will be presenting data on its two novel ADC programs ADCE-T02, targeting Tissue Factor, and ADCE-D01, targeting uPARAP, at the American Association for Cancer […]